GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Accounts Payable & Accrued Expense

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Accounts Payable & Accrued Expense : HK$1,169 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense?

Shenzhen Hepalink Pharmaceutical Group Co's quarterly accounts payable & accrued expense increased from Dec. 2023 (HK$1,047 Mil) to Mar. 2024 (HK$1,209 Mil) but then declined from Mar. 2024 (HK$1,209 Mil) to Jun. 2024 (HK$1,169 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual accounts payable & accrued expense declined from Dec. 2021 (HK$1,352 Mil) to Dec. 2022 (HK$1,212 Mil) and declined from Dec. 2022 (HK$1,212 Mil) to Dec. 2023 (HK$1,047 Mil).


Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 905.04 991.79 1,351.80 1,212.13 1,047.02

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,342.63 956.49 1,047.02 1,209.27 1,169.19

Shenzhen Hepalink Pharmaceutical Group Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


Shenzhen Hepalink Pharmaceutical Group Co Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
Executives
Hong Ze Jun 2101 Beneficial owner
Orbimed Capital Llc 2102 Investment manager
Morgan Stanley & Co. International Plc 2105 Underwriter
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Avict Global Holdings Limited 2101 Beneficial owner
Worldwide Healthcare Trust Plc 2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co Headlines

No Headlines